Genetic Testing Market Segmentation:
by Disease Segment Analysis
The cancer segment is estimated to hold 25% share of the genetic testing market throughout the assessed timeline. The growing prevalence of cancers, owing to genetic inherent, is considered as the major driver of this segment’s proprietorship. It has been clinically proven that if a cancer-risk-raising genetic mutation exists in a parent's sperm or egg cells, it could be transmitted to the newborn. According to the estimations from a 2020 NLM article, over 10.0% of the cancer cases worldwide were diagnosed with hereditary causes. It also mentioned that a cancer-positive family history was discovered among more than 20.0% of residents with malignancy. In such cases, genetic testing is highly recommended for early determination, fueling demand in this sector.
Test Type Segment Analysis
Genetic testing market from the diagnostic testing segment is set to garner a notable share by 2035. The growing incidence of chronic disease that need to be diagnosed at an early stage for better patient outcomes. These medical conditions and their repercussions could frequently be avoided or effectively managed by effective behavior change initiatives, adequate medical therapy, and thorough monitoring. Hence, the need for diagnostic tests is growing, further boosting the segment’s significance in this field. As per NLM, more than 90.0% of the total clinically available genetic tests in the world had the ability to be utilized in diagnosis in 2022.
Our in-depth analysis of the global genetic testing market includes the following segments:
|
Test Type |
|
|
Disease |
|
|
Technology |
|
|
Application |
|
|
Product |
|
